Please login to the form below
CML
This page shows the latest CML news and features for those working in and with pharma, biotech and healthcare.
Merck to acquire Imago BioSciences in deal worth $1.35bn
Additionally, certain MPNs may become acute myeloid leukaemia. MPNs include chronic myelogenous leukaemia (CML), polycythaemia vera (PV), primary myelofibrosis (MF), essential thrombocythaemia (ET), chronic neutrophilic leukaemia and chronic
Latest news
-
Novartis' Scemblix receives EC approval for chronic myeloid leukaemia
It is estimated that more than 6, 300 people will be diagnosed with CML in Europe every year. ... It is estimated that, every year, more than 6, 300 people will be diagnosed with CML in Europe.
-
NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
There are an estimated 830 new cases of CML a year in England and Wales, with most patients needing lifelong treatment and management. ... decades, TKIs have been the mainstay of treatment for CML, however, over time patients often have to switch their
-
Novartis receives approval for third-generation leukaemia therapy
The second indication is in patients with CML who also have the T315I mutation, supported by additional data from a phase 1 trial. ... The approval of Scemblix may offer hope to patients by addressing gaps in CML care.”.
-
Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib
Novartis has been at the forefront of CML research for years – significantly changing the prognosis for patients. ... with newly diagnosed Philadelphia chromosome-positive CML in the chronic phase (Ph+ CML-CP).
-
Novartis' asciminib tops Pfizer's Bosulif in chronic myeloid leukaemia trial
patients with newly diagnosed Philadelphia chromosome-positive CML in the chronic phase (Ph+ CML-CP). ... The US Food and Drug Administration (FDA) has already granted asciminib a fast track designation in CML.
More from news
Approximately 5 fully matching, plus 53 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
as myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML) and solid tumours.
-
Deal Watch January 2017
With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase
-
Deal Watch May 2016
In addition Incyte was granted an exclusive licence to Inclusig [the only approved BCR-ABL inhibitor with activity against the T315I mutation approved in Europe for chronic myeloid leukaemia (CML) and
-
Seismic shifts: Hepatitis C and payers
Analogues such as Glivec (imatanib) which transformed outcomes in CML need to be utilised to demonstrate that tough investment decisions by payers do pay off.
-
Deal Watch table for December 2014
Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph ALL (JP NDA). ... JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia).
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Helen Parfitt joins Research Partnership
She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Spotlight interview: 15 minutes on healthcare advertising
Marie Little, Managing Director, OPEN Health Patient &Brand Communications takes 15 minutes to answer some key questions on healthcare advertising. 1. WHAT IS HEALTHCARE ADVERTISING IN A NUTSHELL? Healthcare advertising follows the same principals
-
Spotlight interview: 15 minutes on patient-centricity in pharma
We have recently developed an above-brand app called “CML Life” which is for patients with chronic myeloid leukaemia.
-
Therapy Watch expands oncology and IBD portfolios
This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the ... US. CML is a rare cancer affecting the white blood
-
Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch
expanded its oncology portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Chronic Myeloid Leukaemia (CML) in 2017.
-
Research Partnership
new Chronic Myelogenous Leukaemia (CML) study in the US.
More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
